Neurogene (NASDAQ:NGNE) Issues Earnings Results

Neurogene (NASDAQ:NGNE) released its quarterly earnings data on Monday. The company reported ($1.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.44, FiscalAI reports.

Neurogene Stock Performance

Neurogene stock opened at $25.31 on Monday. Neurogene has a fifty-two week low of $15.93 and a fifty-two week high of $43.66. The stock has a 50-day simple moving average of $29.46 and a 200-day simple moving average of $27.94. The company has a market capitalization of $506.48 million, a P/E ratio of -5.03 and a beta of 1.75.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on NGNE shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a report on Thursday, October 15th. Guggenheim increased their target price on Neurogene from $69.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. William Blair upgraded shares of Neurogene to a “strong-buy” rating in a report on Wednesday, September 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price target on shares of Neurogene in a research report on Wednesday, October 28th. Finally, Wall Street Zen cut Neurogene from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $80.29.

About Neurogene

Neurogene Inc (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare neurological diseases. The company designs gene therapies intended to address the underlying genetic causes of disorders for which treatment options are limited or unavailable.

Neurogene’s lead program is NGN-401, an investigational gene therapy being developed for Rett syndrome, a rare neurodevelopmental disorder. The company is also advancing NGN-101 for CLN5 Batten disease, a form of neuronal ceroid lipofuscinosis.